Streetbeat News

BTSG

BrightSpring Health Services Inc

Open

17.14

Mkt cap

3B

Volume

735K

High

17.44

P/E Ratio

-193.56

52-wk high

24.82

Low

16.93

Div yield

N/A

52-wk low

8.60

BrightSpring Health Services announced that its specialty pharmacy partner, Onco360, has been chosen as the national pharmacy partner for several new drugs approved for treating advanced cancers and blood diseases.

Portfolio Pulse from

November 26, 2024 | 10:15 pm

BrightSpring Health Services announced that its subsidiary, CareMed, has been chosen as the national specialty pharmacy provider for Leqembi, an Alzheimer's treatment by Eisai. This partnership could enhance BrightSpring's market position.

Portfolio Pulse from

November 06, 2024 | 9:45 pm

BrightSpring Health shares are experiencing an increase in trading value following the company's announcement of an upward revision in its 2024 financial guidance.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 4:07 pm

BrightSpring Health has increased its FY2024 sales guidance from a range of $10.45 billion-$10.90 billion to $11.00 billion-$11.30 billion, surpassing the estimated $10.831 billion.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 10:08 am

BrightSpring Health reported Q3 earnings of $0.11 per share, missing the $0.17 estimate, but sales of $2.91B beat the $2.72B estimate. Earnings increased significantly from last year's loss, and sales grew by 28.80% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 10:06 am

UBS analyst A.J. Rice has maintained a Buy rating on BrightSpring Health (NASDAQ:BTSG) and raised the price target from $16 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:42 pm

Keybanc analyst Matthew Gillmor has initiated coverage on BrightSpring Health (NASDAQ:BTSG) with a Sector Weight rating.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 3:28 pm

BTIG analyst David Larsen maintains a Buy rating on BrightSpring Health (NASDAQ:BTSG) and raises the price target from $15 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:28 pm

Guggenheim has maintained its Buy rating on BrightSpring Health (NASDAQ:BTSG) and raised the price target from $15 to $18.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:18 pm

BrightSpring Health Services announced that KKR & Co. will purchase 11,619,998 shares of BrightSpring's common stock from Walgreen Co. in a private transaction. BrightSpring is not issuing new shares, and the deal is expected to close by September 16, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 8:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.